NMDA Receptor Antagonists Increase the Release of GLP-1 From Gut Endocrine Cells

Type 2 diabetes mellitus (T2DM) remains one of the most pressing health issues facing modern society. Several antidiabetic drugs are currently in clinical use to treat hyperglycaemia, but there is a need for new treatments that effectively restore pancreatic islet function in patients. Recent studie...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Malgorzata Cyranka, Thomas Monfeuga, Natascia Vedovato, Chelsea M Larabee, Anandhakumar Chandran, Enrique M Toledo, Heidi de Wet
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2022-04-01
Edice:	Frontiers in Pharmacology
Témata:	NMDA receptor (NMDAR) Glucagon-like peptide 1 (GLP-1) GLUTag cells MK-801 (dizocilpine) dextromethorphan (DMO), NMDA receptor antagonist
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2022.861311/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!